Cancer Prone Disease Section

Mini Review

Epidermodysplasia verruciformis

Claude Viguié

Service de Dermatologie, Hôpital Tarnier-Cochin, 89 rue d'Assas, 75006 Paris, France

Published in Atlas Database: June 1998

Online updated version is available from: http://AtlasGeneticsOncology.org/Kprones/epiderm_ver.html

DOI: 10.4267/2042/37471

This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence.

© 1998 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Identity

Other names: Levandowsky-Lutz syndrome

Inheritance: autosomal recessive in 10 to 20 % of the patients; other cases are sporadic; rare disease.

Clinics

Epidermodysplasia verruciformis (EV) is a model of malignant transformation from benign cutaneous viral lesion.

Top left: numerous papule-like warts on the skin of an hand; right: other aspect of papule-like warts on one hand; bottom left: basocellular carcinoma of the face developed from epidermodysplasia verruciformis lesions; right: carcinoma of the face developed from epidermodysplasia verruciformis lesions - Courtesy Daniel Wallach.
**Phenotype and clinics**

Age at onset is variable; more frequently: young adults or children. Two types of elementary cutaneous lesions are observed:
- Persistent papule-like warts, isolated, or confluent with a psoriasic aspect;
- White spots, pityriasis versicolor-like.
Both types of lesions are localized mainly on the outer part of the hands, on forearms, legs, face, trunk and perianal zone.

Immune deficiency: decreased immune response of T lymphocytes to mitogens, decreased humoral response to Human Papilloma Virus antigens; EV lesions have been described in renal transplant recipients.

Various Human Papilloma Virus (HPV) subtypes are regularly detected in the cutaneous lesions: HPV 5, 8, 9, 12, 14, 15, 17, 19, 25, 36, 38, 47, 50.

Patients are simultaneously affected by different HPV subtypes, according to disease localisation; these subtypes are different from those observed in common warts (HPV 2, 3, 4, 10).

**Neoplastic risk**

Risk of malignant transformation of cutaneous lesions is within a delay of 20 to 30 yrs (very slow process comparable to the genital carcinogenesis associated with high risk HPV).

Cytology: squamous cell carcinoma (spinocellular or basocellular carcinoma, Bowen disease).

Correlation with oncogenic subtypes of HPV found in the transformed lesions: HPV 5, 8, 14; the most frequent subtypes are HPV 5 and 8 (90% of cases).

Benign familial forms are associated with HPV 3, without malignant evolution.

HPV-5 is present in the macular lesions.

Probable potentialisation by UV light: 25 to 30% of malignant lesions localised to the face and forehead (hypothetic role of P53 mutations).

Protein E6 and/or E7 (tumour suppressor function) from HPV seem to be involved in the malignant transformation.

**Treatment**

Surgical resection of localized lesions; chemotherapy with Acitretin (25 mg/j) for multifocal lesions.

**Evolution**

Local recidives, enhanced by UV exposition.

**Genes involved and Proteins**

Complementation groups:

Genes and proteins are unknown.

**References**


